Estimaciones de analistas de Wall Street para Accuray Incorporated (ARAY): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-0.07 | ||
| 2026-08-19 | $-0.02 | $-0.03 | +33.3% |
| 2026-05-06 | $-0.09 | $-0.05 | -80.0% |
| 2026-02-04 | $-0.11 | $-0.11 | -2.2% |
| 2025-11-05 | $-0.18 | $-0.01 | -1700.0% |
| 2025-08-13 | $0.01 | $0.03 | -65.6% |
| 2025-04-30 | $-0.01 | $-0.05 | +80.0% |
| 2025-02-05 | $0.02 | $-0.01 | +300.0% |
Ratios de valoración
| Precio / Valor contable | 0.67 |
| EV / EBITDA | -12.16 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $383.4M | $404.9M | $418.8M | $382.9M | $396.3M | $429.9M | $447.6M | $446.6M | $458.5M | $401.9M |
| Coste de Ventas | $242.1M | $243.2M | $256.1M | $233.2M | $236.8M | $270.0M | $293.6M | $303.6M | $311.5M | $290.5M |
| Beneficio Bruto | $141.3M | $161.7M | $162.7M | $149.7M | $159.5M | $160.0M | $154.0M | $142.9M | $147.0M | $111.5M |
| I+D | $49.9M | $57.3M | $56.5M | $49.8M | $52.7M | $57.8M | $57.1M | $49.7M | $47.9M | $37.8M |
| Generales y Administrativos | $101.2M | $108.2M | $105.6M | $87.4M | $84.5M | $94.1M | $94.4M | $92.7M | $91.2M | $84.0M |
| Gastos Operativos | $151.2M | $165.5M | $162.1M | $137.2M | $137.3M | $151.8M | $151.6M | $142.4M | $139.1M | $137.9M |
| Beneficio Operativo | -$9.8M | -$3.8M | -$9.9M | $12.5M | $22.2M | $8.1M | $2.4M | $504000 | $7.8M | -$26.4M |
| EBITDA | $6.8M | $1.7M | $11.1M | $31.3M | $18.7M | $11.6M | $8.4M | $5.7M | $20.2M | -$14.3M |
| Gastos por Intereses | $17.3M | $15.0M | $15.1M | $18.1M | $16.9M | $8.1M | $10.6M | $11.6M | $13.0M | $35.3M |
| Beneficio Antes de Impuestos | -$28.5M | -$23.0M | -$14.3M | $5.7M | -$4.6M | -$2.0M | -$6.8M | -$11.8M | $1.1M | -$47.2M |
| Impuestos | $1.0M | $878000 | $2.1M | $1.9M | $1.8M | $3.3M | $2.5M | $3.7M | $2.7M | $1.9M |
| Beneficio Neto | -$29.6M | -$23.9M | -$16.4M | $3.8M | -$6.3M | -$5.3M | -$9.3M | -$15.5M | -$1.6M | -$49.2M |
| BPA | $-0.36 | $-0.28 | $-0.19 | $0.04 | $-0.07 | $-0.06 | $-0.10 | $-0.16 | $-0.02 | $-0.40 |
| BPA Diluido | $-0.36 | $-0.28 | $-0.19 | $0.04 | $-0.07 | $-0.06 | $-0.10 | $-0.16 | $-0.02 | $-0.40 |
| Acciones en Circulación (Diluidas) | $82.5M | $84.9M | $87.5M | $90.6M | $92.0M | $92.1M | $94.9M | $98.3M | $102.8M | $122.6M |
Precio
| Precio | $0.23 |
| Capitalización | $28M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ANIK · AVR · LNSR · MIST · MXCT · OWLT · PROF
Explorar sector: Healthcare · Medical - Devices
Más secciones de ARAY: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones